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Abstract
We here present descriptions of two patients who after bleeding to the central nervous system sustained pulmonary 
embolisms, and we discuss the therapeutic difficulties connected with the choice of safe antithrombotic treatment in 
acute pulmonary embolism.
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Introduction
Symptoms of venous thromboembolism (VTE) include deep 
vein thrombosis and pulmonary embolism (PE). Pulmonary 
embolism is, after coronary artery disease and ischaemic 
stroke, the third most frequent cause of death due to 
cardiovascular causes. In the general population, its preva-
lence is estimated at 71–117 cases per 100,000 people 
[1, 2]. This disease is caused by a sudden closure or nar-
rowing of the pulmonary artery or its branches by embolic 
material, which typically comes from deep veins of the lower 
extremities or the lesser pelvis. Less frequently, thrombi 
may come from veins in the upper part of the body or from 
right cardiac chambers [3, 4]. Factors which most strongly 
predispose towards PE, included in the Wells score and the 
modified Geneva score, are: a history of VTE, major surgery, 
immobilisation, thrombophilias, cancer and old age [4, 5].
Antithrombotic therapy is recommended for PE patients 
in order to prevent sudden death and recurrence of VTE. 
Currently, heparins and fondaparinux (5–10 mg once daily) 
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chest revealed embolic material in arteries up to the upper 
and lower lobe of the left lung and all lobes of the right 
lung (Figure 2). No clinical features of venous thrombosis 
of the lower extremities were identified. After admission to 
cardiology department, the patient suffered from intermit-
tent respiratory failure; dyspnoea and reduced saturation 
were observed, and passive oxygenation was employed. 
During the first days of PE, enoxaparin was administered 
at a therapeutic dose of 80 mg twice daily (1 mg/kg body 
weight, twice daily). In addition, MRI of the head indicated 
innumerable small foci of hypointensity corresponding to 
haemosiderin deposits caused by past small haemorrhages 
in both cerebral hemispheres, within the cerebellum and 
are registered in PE treatment, as well as vitamin K an-
tagonists (therapeutic INR of 2.0–3.0 is the goal) (VKAs), 
apixaban, (10 mg twice daily), dabigatran (150 mg twice 
daily), edoxaban (60 mg once daily) and rivaroxaban (15 mg 
twice daily) in oral therapy [6].
Case reports
Patient 1.
An obese 80 year-old patient, with coronary syndrome, 
arterial hypertension, hypothyroidism and type 2 diabetes, 
was admitted to the clinic of cardiology due to PE. The 
patient was hospitalised in the neurology department due 
to weakness which had been progressing for a month, 
experienced especially strongly in the upper and lower 
extremities. Upon admission, the patient was diagnosed 
with flaccid quadriparesis. Magnetic resonance imaging 
(MRI) of the spine showed a 14 × 10 mm cavernous an-
gioma with features of a haemorrhage at the level of the 
second cervical vertebra (C2), while below, within the cord, 
a 8.5 × 75 mm hyperintensive lesion, reaching all the way 
to the seventh cervical vertebra (C7), was imaged, which 
also corresponded to a haemorrhage (Figure 1). On the 
third day, the patient experienced sudden dyspnoea at 
rest. An electrocardiogram (ECG) revealed no features of 
acute myocardial ischaemia. Laboratory tests indicated 
an extremely high D-dimer concentration of 37,594 μg/L 
(normal concentration 0–500 μg/L) and correct levels of 
myocardial necrosis markers and B-type natriuretic peptide 
(BNP). The echocardiogram showed no features of right 
ventricular volume overload or left ventricular systolic dys-
function. Computed tomography angiography (CTA) of the 
Figure 1. Patient 1. T2-weighted magnetic resonance images; head — left frontal area; cord — lesion between medulla oblongata and spinal 
cord at C2 vertebra level, with haemorrhage up to body of C7 vertebra
A B
Figure 2. Patient 1. Computed tomography angiography of chest — 
embolic material in pulmonary arteries
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in the midbrain and the brainstem. The patient underwent 
neurosurgery consultation due to numerous comorbidities 
suggesting an unfavourable course of the periprocedural 
period and extensive nature of the syringomyelic cavity. The 
patient was qualified for conservative treatment.
On the sixth day of hospitalisation, the patient was re-
turned to the neurology clinic for further treatment. When 
the patient was discharged, after a week-long hospital stay 
and following neurosurgery and cardiology consultations, 
continued enoxaparin treatment was recommended, at 
a dose reduced to 40 mg twice daily due to a high risk 
of repeated central nervous system (CNS) haemorrhage. 
During observation over three months, the patient has re-
mained stable; low-molecular-weight heparin (LMWH) is 
being administered.
Patient 2.
This 74 year-old patient with arterial hypertension was ad-
mitted to the cardiology department due to PE. On the fifth 
day of the stay at the clinic of neurology where the patient 
was hospitalised due to intracerebral haemorrhage (Figu-
re 3), the patient was awoken by sudden dyspnoea. ECG 
revealed no features of acute myocardial ischaemia; sinus 
tachycardia and inverted T waves in precordial leads were 
observed. Myocardial necrosis marker and BNP levels were 
correct, while D-dimer concentration was, in fact, elevated, 
at 3,500 μg/L. Among irregularities which suggested right 
ventricular volume overload, the echocardiogram indicated 
only a shortened acceleration time (ACT) of flow through the 
pulmonary valve — 78 ms, with narrowing on the ascending 
limb. CTA of the chest revealed embolic material located 
in the pulmonary trunk, at the point of bifurcation into 
the right and left pulmonary arteries (a so-called ‘saddle’ 
embolism) (Figure 4). The patient was administered LMWH 
at a dose of 60 mg twice daily (1 mg/kg body mass twice 
daily). A follow-up CT of the head revealed a malacic cavity 
caused by an intracerebral haematoma, but no features 
of an active haemorrhage (Figure 5). Dyspnoea subsided 
completely during hospitalisation, and symptoms of he-
miparesis had been slightly weakening. The patient was 
discharged in a stable general condition, with sufficient 
cardiorespiratory function and a recommendation to take 
enoxaparin at a dose of 60 mg twice daily and undergo 
Figure 3. Computed tomography of head without contrast agent — 
intracerebral haematoma in deep structures on left
Figure 4. Patient 2. Computed tomography angiography of chest: 
a ‘saddle’ embolism
Figure 5. Computed tomography of head following diagnosis of 
pulmonary embolism — malacic cavity caused by intracerebral 
haemorrhage
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PE (one of the patients was diagnosed with a ‘saddle’ em-
bolism); on the other hand, administration of antithrom-
botic drugs adversely affects the size of haemorrhagic 
CNS foci [10]. Because there have been no large-scale, 
controlled clinical trials, the subject issue remains an 
unresolved multidisciplinary problem for both cardiolo-
gists and neurologists. There is also no literature which 
links the issue of haemorrhagic vascular malformations 
with PE. Assuming that PE in the presented patients was 
caused by an identified factor — immobilisation — then, 
in accordance with the current guidelines, antithrombotic 
therapy should be continued for at least three months 
[6]. A history of CNS haemorrhage was the strongest de-
terminant behind the selection of antithrombotic treat-
ment. Medicinal product characteristics for all NOACs 
list vascular malformations as a contraindication against 
their administration. Inclusion of VKAs for the subject 
patients was also impossible due to difficulty in predic-
ting the effect of action, and contraindications against 
their use in the acute phase of CNS haemorrhage. 
LMWH, which is preferred over UFH, remained the saf-
est treatment, as its administration entails a lower risk 
of severe haemorrhage and heparin-induced thrombo-
cytopenia [11]. For subject patients, therapeutic doses 
of enoxaparin were administered during the initial days 
of PE; the dose for the patient with vascular malforma-
tions was reduced at discharge due to the high risk of 
repeated haemorrhage.
Summary
The optimisation of treatment in acute PE for patients after 
a CNS haemorrhage has been based on monitoring the 
parameters of cardiovascular function and neurological 
condition; neurological examinations and imaging tests 
were performed repeatedly, and the patient with vascular 
malformations also underwent neurosurgery consulta-
tion. In September this year, the ENRICH-AF (EdoxabaN 
foR IntraCranial Haemorrhage survivors with Atrial Fibril-
lation) study began; it is devoted to the issue of safety of 
antithrombotic therapy using edoxaban for patients with 
atrial fibrillation after an intracranial haemorrhage. We 
are hoping that it will contribute to a better understand-
ing and selection of appropriate therapy for patients for 
whom antithrombotic therapy is simultaneously indicated 
and contraindicated.
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a neurology consultation six weeks after discharge in or-
der to consider whether an oral anticoagulant should be 
administered. Over a one-month observation, the patient 
has remained stable.
Discussion
Pulmonary embolism is a symptom of VTE and a condition 
which requires antithrombotic therapy [6]. Modern pharma-
cological treatment of PE already in the acute phase can 
begin with the administration of non-vitamin K antagonist 
oral anticoagulants (NOACs).
According to the latest guidelines of the European So-
ciety of Cardiology (ESC) concerning PE, for those patients 
from the low-risk group with PE for whom it is possible to 
administer oral coagulants, these drugs are preferred over 
VKAs. On the other hand, for patients from the low-risk 
group for whom treatment begins with parenteral therapy, 
LMWH and fondaparinux are preferred over unfractionated 
heparin (UFH) [6].
The subject patients were diagnosed with low-risk 
PE. The patients were similar in that for both the disease 
occurred after a CNS haemorrhage; consequently, their 
similarity extended to contraindications against standard 
treatment regimens for the acute phase of PE. Cerebral 
vascular malformations are a group of congenital and ac-
quired abnormalities of cerebral vessels heterogeneous in 
structure and function. Due to the increasing availability 
of imaging tests, they are detected more and more fre-
quently [7]. Cavernous angiomas found in Patient 1 are 
a rare form of CNS vascular malformations, occurring in 
0.6% of the general population [8]. CNS haemorrhage of 
cavernous angiomas is the rarest symptom of these mal-
formations; they typically manifest themselves through 
headaches or epileptic seizures, and the vast majority of 
affected people remain asymptomatic for their entire lives 
[9]. In the case of the subject patient, numerous haem-
orrhages, which manifested themselves fairly late, in the 
ninth decade of life, resulted in immobilisation, which 
probably predisposed towards PE. Patient 2 suffered an 
intracerebral haemorrhage probably due to improper man-
agement of arterial hypertension. Haemorrhagic stroke 
is a condition which constitutes an immediate threat to 
life. Between 30% and 50% of patients die within the first 
30 days, wherein half of deaths happen within the first 
two days of occurrence [10].
Our two presented cases illustrate the difficulty con-
cerning the administration of antithrombotic therapy in 
the acute phase of PE for patients with CNS haemor-
rhage. On the one hand, not administering antithrombotic 
drugs entails an increased risk of death in the course of 
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Streszczenie
Przedstawiono opisy 2 chorych, którzy po krwawieniu do ośrodkowego układu nerwowego doznali zatorowości płucnej, 
oraz trudności terapeutyczne związane z wyborem bezpiecznego leczenia przeciwkrzepliwego w ostrej zatorowości 
płucnej.
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